Genetic Tumor Profiling and Genetically Targeted Cancer Therapy

Seminars in Oncology Nursing

Volumn 27, Issue 1, 2011, Pages 34-44

  Goetsch, Cathleen M ^a  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

DNA microarray assay; Epigenetics; Gene expression profiling; Targeted therapy

Indexed keywords

ARTICLE; CLINICAL COMPETENCE; EDUCATION; FEMALE; FORECASTING; GENE EXPRESSION PROFILING; GENE THERAPY; GENETICS; HUMAN; MALE; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; NURSE ATTITUDE; NURSING; ONCOLOGY NURSING; TREATMENT OUTCOME;

CLINICAL COMPETENCE; FEMALE; FORECASTING; GENE EXPRESSION PROFILING; GENE THERAPY; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NURSE'S ROLE; ONCOLOGIC NURSING; TREATMENT OUTCOME;

EID: 78751477129     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2010.11.005     Document Type: Article

References (62)

1. Illei P.B., Westra W. Principles of oncologic surgical pathology. Abeloff's clinical oncology 2008, 233-239. Churchill Livingston Elsevier, Philadelphia, PA. Ed 4. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
2. Offit K., Thom P., Bernstein D. Genetic factors: hereditary cancer predisposition syndromes. Abeloff's clinical oncology 2008, 171-192. Churchill Livingston Elsevier, Philadelphia, PA. Ed 4. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
3. de Jong D., Xie W., Rosenwald A., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol 2009, 62:128-138.
4. Cody L.D., Wilson K.S. Conventional and molecular cytogenetics of neoplasia. Abeloff's clinical oncology 2008, 249-263. Churchill Livingston Elsevier, Philadelphia, PA. Ed 4. M.D. Abeloff, J.O. Armitage, J.E. Niederhuber, M.B. Kastan, W.G. McKenna (Eds.).
5. Esteva F.J., Sahin A.A., Cristofanill M., et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin Cancer Res 2005, 11:3315-3319.
6. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826.
7. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
8. ®: phase III randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence (TAILORx Trial) National Cancer Institute, Available at, (accessed Feb 25, 2010). http://www.cancer.gov/clinicaltrials/ECOG-PACCT-1.
9. Mamounas E.P., Tang G., Fisher B., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol 2010, 28:1677-1683.
10. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
11. Foekens J.A., Atkins D., Zhang Y., et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006, 24:1665-1671.
12. Liu R., Wang X., Chen G.Y., et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 2007, 356:217-226.
13. Ma X.J., Wang Z., Ryan P.D., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004, 5:607-616.
14. Ma X.J., Salunga R., Dahiya S., et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008, 14:2601-2608.
15. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96. Available at, (accessed Oct 8, 2010). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1468408/pdf/1471-2164-7-96.pdf.
16. Sørlie T., Perou C.M., Fan C., et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006, 5:2914-2918.
17. Liu J., Campen A., Huang S., et al. Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data. BMC Med Genomics 2008, 1:39. Available at, (accessed Oct 8, 2010). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551605/pdf/1755-8794-1-39.pdf.
18. Mosley J.D., Keri R.A. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. BMC Med Genomics 2008, 1:11. Available at, (accessed Oct 8, 2010). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2396170/pdf/1755-8794-1-11.pdf.
19. Sparano J.A., Solin L.J. Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. J Clin Oncol 2010, 28:1625-1627.
20. Lo S.S., Mumby P.B., Norton J., et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 2010, 28:1671-1676.
21. Kerr D., Gray R., Quirke P., et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 2009, 27(suppl):15s. [abstract 4000].
22. O'Connell MJ, Lavery IC, Gray RG, et al. Comparison of molecular and pathologic features of stage II and stage III colon cancer in four large studies conducted for development of the 12-gene colon cancer recurrence score [abstract 280]. American Society of Clinical Oncologists 2010 Gastrointestinal Cancers Symposium; January 22-24, 2010, Orlando, FL. Available at: (accessed Feb 17, 2010). http://www.asco.org/ASCOv2/Meetings/Abstracts?%26vmview=abst_detail_view%26confID=72%26abstractID=2334.
23. Roth A.D., Tejpar S., Yan P., et al. Stage-specific prognostic value of molecular markers in colon cancer: results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial. J Clin Oncol 2009, 27(suppl):15s. [abstract 4002].
24. Rosenwald A., Wright G., Leroy K., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:851-862.
25. Alizadeh A., Eisen M., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
26. Rosenwald A., Wright G., Chan W.C., et al. for the Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy of diffuse large B cell lymphoma. N Engl J Med 2002, 346:1937-1947.
27. Jabłońska J., Jesionek-Kupnicka D. Usefulness of immunohistochemistry in identification of prognostically important subgroups (GCB and ABC) in a heterogeneous group of diffuse large B-cell lymphomas-a review article. Pol J Pathol 2008, 59:121-127.
28. Anguiano A., Tuchman S.A., Acharya C., et al. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009, 27:4197-4203.
29. Hurt E.M., Wiestne A., Rosenwald A., et al. Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell 2004, 5:191-199.
30. Rosenwald A., Alizadeh A.A., Widhopf G., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1648.
31. Dufour A., Schneider F., Metzeler K.H., et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010, 28:570-577.
32. Swerdlow S.H., Campo E., Harris N.L., et al. Classification of Tumours of the Haematopoietic and Lymphoid Tissues 2008, WHO Press, Geneva, Switzerland. Ed 4.
33. NCCN clinical practice guidelines in oncology: acute myeloid leukemia.v.2.2010 National Comprehensive Cancer Network (NCCN), Available at, (accessed June 14, 2010). http://www.nccn.org/professionals/physician_gls/PDF/aml.pdfhttp://www.nccn.org/professionals/physician_gls/PDF/aml.pdf.
34. Hancock J.T. Cell signaling 2005, Oxford Press, New York, NY. Ed 2.
35. Bang Y., Chung H., Sawaki A., et al. HER2-positivity rates in advanced gastric cancer (GC): results from a large international phase III trial. J Clin Oncol 2008, 26(suppl):15. [abstract 4526].
36. Schuell B., Gruenberger T., Scheithauer W., et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer 2006, 8:123. Available at, (accessed Oct 8, 2010). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1475876/pdf/1471-2407-6-123.pdf.
37. Eltze E., Wülfing C., Von Struensee D., et al. Cox-2 and Her2/neu co-expression in invasive bladder cancer. Int J Oncol 2005, 26:1525-1531.
38. McKenzie S.J., DeSombre K.A., Bast B.S., et al. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 1993, 71:3942-3946.
39. Hetzel D.J., Wilson T.O., Keeney G.L., et al. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992, 47:179-185.
40. Hirashima N., Takahashi W., Yoshii S., et al. Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 2001, 14:556-662.
41. Mitra A.B., Murty V.V.S., Pratap M., et al. ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. Cancer Res 1994, 54:637-639.
42. Beckhardt R.N., Kiyokawa N., Xi L., et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995, 121:1265-1270.
43. Reichelt U., Duesedau P., Tsourlakis M.C., et al. Frequent homogenous HER-2 amplification in primary and metastatic adenocarcinomas of the esophagus. Mod Path 2007, 20:120-129.
44. LoRusso P.M., Ryan A.J., Boerner S.A., et al. Small molecule tyrosine kinase inhibitors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology 2008, 457-458. Lippincott, Williams & Wilkins, Philadelphia, PA. Ed 8. V.T. DeVita, T.S. Lawrence, S.A. Rosenberg, R.A. Weinberg, R.A. DePinho (Eds.).
45. Amado R., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 10:1626-1634.
46. Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. J Clin Oncol 2008, 26(suppl):15s. [abstract 4000].
47. Van Cutsem E., Lang I., D'haens G. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008, 26(suppl):15s. [abstract 2].
48. Yen L.C., Uen Y.H., Wu D.C., et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010, 251:254-260.
49. Nguyen S., Hoang V., Laquer V., et al. Angiogenesis in cutaneous disease: part I. J Am Acad Dermatol 2009, 61:921-942.
50. Sharma S., Kelly T.K., Jones P.A. Epigenetics in cancer. Carcinogenesis 2010, 31:27-36.
51. Beier V., Mund C., Hoheisel J.D. Monitoring methylation changes in cancer. Adv Biochem Eng Biotechnol 2007, 104:1-11.
52. Egger G., Liang G., Aparicio A., et al. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429:457-463.
53. Shabason J.E., Tofilon P.J., Camphausen K. HDAD inhibitors in cancer care. Oncology 2010, 24:180-188.
54. Ropero S., Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007, 1:19-25.
55. Smith K.T., Workman J.L. Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol 2009, 41:21-25.
56. Gillenwater A.M., Zhong M., Lotan R. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 2007, 6:2967-2975.
57. Stamatopoulos B., Meuleman N., De Bruyn C., et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis, downregulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010, 95:1136-1143.
58. Takai N, Narahara H. Preclinical studies of chemotherapy using histone deacetylase inhibitors in endometrial cancer. Obstet Gynecol Int [ePub ahead of print Feb. 4, 2010]. Available at: (accessed Feb. 24, 2010). http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821626/?tool=pubmed.
59. Sakamoto K.M. Targeting ubiquitin and ubiquitin-like modifier pathways for cancer therapy. American Society of Clinical Oncology 2009 Education Book Available at, (accessed Sept. 16, 2010). http://www.asco.org/ASCOv2/Education+%26+Training/Educational+Book?&vmview=edbk_detail_view&confID=65&abstractID=28.
60. Dlugosz A.A., Talpaz M. Following the hedgehog to new cancer therapies. N Engl J Med 2009, 361:1202-1205.
61. Comen E.A., Robson M. Inhibition of poly (ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology 2010, 24:56-61.
62. Wilkes G.M. Drug essentials: PARP inhibitors in BRCA-associated cancers. Oncology Nurse Edition 2010, 24:55-56.